文献速递疼痛医学区域麻醉与超声

超声引导经皮颧上翼腭神经节阻滞联合无创迷走神经刺激对难治性原发性及继发性头痛的显著疗效:病例系列

Refractory primary and secondary headache disorders that dramatically responded to combined treatment of ultrasound-guided percutaneous suprazygomatic pterygopalatine ganglion blocks and non-invasive vagus nerve stimulation: a case series.
PubMed 文献 · Reg Anesth Pain Med · 2024-02-05

本文报告9例难治性原发性头痛及硬膜外血补片抵抗的硬脊膜穿刺后头痛患者,接受超声引导经皮颧上翼腭神经节阻滞,其中7例联合无创迷走神经刺激,症状获得戏剧性、即刻、满意且看似持久的缓解,作者主张将该方案作为一线或二线治疗而非最后手段。

要点

  • 超声引导经皮颧上翼腭神经节阻滞联合无创迷走神经刺激可使难治性头痛迅速缓解。
  • 该方案对硬脊膜穿刺后头痛及原发性头痛均可能有效。
  • 作者建议将其作为一线或二线治疗,而非绝望时的最后选择。

核心结论

  • 超声引导经皮颧上翼腭神经节阻滞联合无创迷走神经刺激对难治性原发性头痛和硬脊膜穿刺后头痛产生戏剧性、即刻、满意且看似持久的症状缓解。
  • 作者主张将该联合方案作为硬脊膜穿刺后头痛和原发性头痛的一线或二线治疗,而非最后手段。

研究设计与样本

  • 病例系列,纳入9例难治性头痛患者(共11个长期难治性原发性头痛诊断及硬膜外血补片抵抗的硬脊膜穿刺后头痛),患者为随机选取且非研究组成部分。
  • 所有患者接受超声引导经皮颧上翼腭神经节阻滞,其中7例同时接受无创迷走神经刺激。

主要发现

  • 患者经历戏剧性、即刻、满意且(截至报告撰写时)看似持久的症状缓解。
  • 报告提供了病例描述,简要回顾了三叉血管和神经源性炎症病理生理理论,并概述了翼腭神经节阻滞和无创迷走神经刺激干预的各方面。

关键数值与推荐

  • 1981年Devoghel通过经皮颧上入路酒精化翼腭神经节治疗难治性丛集性头痛,成功率达85.6%。
  • 无创迷走神经刺激已被国家监管机构批准用于治疗丛集性头痛和偏头痛等。

临床怎么用

  • 对于难治性原发性头痛和硬脊膜穿刺后头痛,可考虑超声引导经皮颧上翼腭神经节阻滞联合无创迷走神经刺激。
  • 该联合方案可作为一线或二线治疗选择,而非仅作为最后手段。

局限性

  • 本文为病例系列,患者为随机选取且非研究组成部分,未设立对照组。
  • 样本量小(9例患者,11个诊断),疗效的持久性截至报告撰写时仅为初步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 1981, Devoghel achieved an 85.6% success rate in treating patients with treatment-refractory cluster headaches with alcoholization of the pterygopalatine ganglion (PPG) via the percutaneous suprazygomatic approach. Devoghel's study led to the theory that interrupting the parasympathetic pathway by blocking its transduction at the PPG could prevent or treat symptoms related to primary headache disorders (PHDs). Furthermore, non-invasive vagus nerve stimulation (nVNS) has proven to treat PHDs and has been approved by national regulatory bodies to treat, among others, cluster headaches and migraines.In this case series, nine desperate patients who presented with 11 longstanding treatment-refractory primary headache disorders and epidural blood patch-resistant postdural puncture headache (PDPH) received ultrasound-guided percutaneous suprazygomatic pterygopalatine ganglion blocks (PPGB), and seven also received nVNS. The patients were randomly selected and were not part of a research study. They experienced dramatic, immediate, satisfactory, and apparently lasting symptom resolution (at the time of the writing of this report). The report provides the case descriptions, briefly reviews the trigeminovascular and neurogenic inflammatory theories of the pathophysiology, outlines aspects of these PPGB and nVNS interventions, and argues for adopting this treatment regime as a first-line or second-line treatment rather than desperate last-line treatment of PDPH and PHDs.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Boezaart AP, Smith CR, Zasimovich Y, et al. Refractory primary and secondary headache disorders that dramatically responded to combined treatment of ultrasound-guided percutaneous suprazygomatic pterygopalatine ganglion blocks and non-invasive vagus nerve stimulation: a case series. Reg Anesth Pain Med. 2024. PMID: 37989499. doi:10.1136/rapm-2023-104967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。